Urogen Pharma Ltd (URGN) |
|
21.37 0.9 (4.4%)
|
10-24 13:45 |
|
Open: |
20.67 |
Pre. Close: |
20.47 |
|
High:
|
21.52 |
Low:
|
20.4 |
|
Volume:
|
52,795 |
Market Cap:
|
471M |
|
|
|
|
UroGen Pharma Ltd. is a clinical stage pharmaceutical company, which engages in the provision of non-surgical and localized solutions for urological pathologies to address a clinical unmet need in field of uro-oncology. The company is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidates include Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). Its platform technologies include: RTGel and Immunotherapy. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
21.54 - 21.623 |
21.623 - 21.718 |
|
Low:
|
20.181 - 20.267 |
20.267 - 20.367 |
|
Close:
|
21.203 - 21.347 |
21.347 - 21.513 |
|
Technical analysis |
as of: 2020-10-23 4:50:00 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 27.38 One year: 31.98 |
| Support: |
Support1: 20.30 Support2: 18.36 |
| Resistance: |
Resistance1: 23.44 Resistance2: 27.38 |
| Pivot: |
21.72 |
| Moving Average: |
MA(5): 21.30  MA(20): 21.11
MA(100): 23.31 MA(250): 25.32 |
| MACD: |
MACD(12,26): 0.07 Signal(9): 0.12 |
| Stochastic oscillator: |
%K(14,3): 34.60 %D(3): 43.21 |
| RSI: |
RSI(14): 49.82 |
| 52-week: |
High: 35.21 Low: 13.12 Change(%): -5.3 |
| Average Vol(K): |
3-Month: 15560 10-Days: 8079 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.URGN has closed above bottom band by 41.1%. Bollinger Bands are 17.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Thu, 08 Oct 2020
Urogen Pharma (NASDAQ:URGN) Upgraded by BidaskClub to Hold - MarketBeat
Mon, 05 Oct 2020
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Sat, 03 Oct 2020
$3.21 Million in Sales Expected for Urogen Pharma Ltd (NASDAQ:URGN) This Quarter - MarketBeat
Thu, 01 Oct 2020
UroGen Pharma Ltd. (NASDAQ:URGN): Are Analysts Optimistic? - Simply Wall St
Mon, 10 Aug 2020
UroGen Pharma Reports Second Quarter 2020 Financial Results and Recent Corporate Developments - Business Wire
Mon, 10 Aug 2020
UroGen Pharma Ltd. (URGN) Q2 2020 Earnings Call Transcript - Motley Fool
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
22 |
| Shares Float (M) |
19 |
|
% Held by Insiders
|
12.42 |
|
% Held by Institutions
|
81.28 |
|
Shares Short (K)
|
3,200 |
|
Shares Short P. Month (K)
|
3,130 |
Stock Financials |
|
EPS
|
-6.150 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
6.480 |
|
Profit Margin
|
|
|
Operating Margin
|
-34154.03 |
|
Return on Assets (ttm)
|
-39.7 |
|
Return on Equity (ttm)
|
-71.0 |
|
Qtrly Rev. Growth
|
1966.7 |
|
Gross Profit (p.s.)
|
0.001 |
|
Sales Per Share
|
0.017 |
|
EBITDA (p.s.)
|
-5.754 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-98 |
|
Levered Free Cash Flow (M)
|
-47 |
Stock Valuations |
|
PE Ratio
|
-3.47 |
|
PEG Ratio
|
|
|
Price to Book value
|
3.30 |
|
Price to Sales
|
1264.97 |
|
Price to Cash Flow
|
-4.80 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
